NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
Rhea-AI Summary
NeuroSense (Nasdaq: NRSN) reported 2025 results and a business update. PrimeC advanced to a late-stage asset with FDA clearance to start the Phase 3 PARAGON trial and Phase 2b PARADIGM showed ~33% slowing of progression over 18 months.
In early 2026 the company reported a 65% reduction in risk of death and a >14-month median survival benefit; results were published in JAMA Neurology. Financials show $0.2M cash at Dec 31, 2025 and a $11.125M net loss for 2025. Key near-term milestones include a May 2026 pre-NDS meeting in Canada and Alzheimer’s readouts.
Positive
- FDA clearance to initiate Phase 3 PARAGON
- 65% reduction in risk of death reported
- Publication in JAMA Neurology
Negative
- Cash and cash equivalents of $0.2M at Dec 31, 2025
- Net loss of $11.125M in 2025
- Total assets declined from $4.575M to $1.028M
News Market Reaction – NRSN
In the Mar 31 session, NRSN gained 3.28%, reflecting a moderate positive market reaction. Argus tracked a peak move of +30.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 07 | FY 2024 results | Positive | -2.3% | Reported FY 2024 results with strong Phase 2b ALS data and regulatory alignment. |
| Dec 18 | Q3 2024 results | Positive | +4.6% | Q3 2024 update with PARADIGM completion, private placement and FDA feedback. |
| Jun 24 | Q1 2024 results | Positive | -5.9% | Q1 2024 results showing significant slowing of ALS progression and funding raise. |
| May 02 | Q1 2024 update | Neutral | +0.8% | Q1 2024 business update focused on collaborations and PARADIGM progress. |
| Apr 05 | FY 2023 results | Neutral | -17.5% | Year-end 2023 financial results and business update without detailed summary provided. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and business updates have often seen negative or muted next-day reactions, even when operational news on PrimeC was positive.
Across prior earnings-tagged updates since April 2024, NeuroSense has repeatedly paired clinical progress for PrimeC with tight cash positions and ongoing losses. Full-year 2024 results on Apr 07, 2025 highlighted encouraging ALS efficacy and survival signals but still saw a share price decline. Quarterly 2024 updates mixed trial advances, new financing and Canadian commercialization plans with continued net losses. The current 2025 results extend this pattern: stronger late-stage positioning for PrimeC alongside a thin balance sheet.
Key Terms
phase 2b medical
phase 3 medical
als medical
biomarker medical
microrna medical
median survival medical
pre-nds regulatory
form 20-f regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS
- Statistically significant survival benefit demonstrated, including
65% reduction in risk of death and >14-month median survival advantage - Results published in JAMA Neurology, providing high-level peer-reviewed validation of clinical and biological activity
- Advancing toward key regulatory milestones with planned pre-NDS meeting in
Canada and near-term Alzheimer's readout
"2025 was a transformational year for NeuroSense, as we advanced PrimeC from a successful Phase 2b program into a late-stage clinical asset with a clear regulatory path forward," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "As we entered 2026, we further strengthened our clinical and scientific foundation with statistically significant survival data and publication of our results in JAMA Neurology. Together, these milestones position PrimeC as a differentiated therapeutic candidate with the potential to meaningfully impact people with ALS and potentially other neurodegenerative diseases."
Business Highlights from 2025
2025 marked a transformative year for NeuroSense, as the Company advanced PrimeC from a successful Phase 2b program into a late-stage clinical asset with a clearly defined regulatory and development pathway. Results from the Phase 2b PARADIGM study demonstrated approximately
The Company also completed commercial-scale manufacturing and advanced its regulatory strategy, including engagement with Health Canada and ongoing partnership discussions.
Importantly, in November 2025, NeuroSense received FDA clearance to initiate the PARAGON Phase 3 trial in ALS, marking a key inflection point in the Company's development trajectory.
NeuroSense also reported early signals of biological activity and statistically significant reductions in key biomarkers associated with Alzheimer's disease, supporting broader potential across neurodegenerative diseases.
Recent Developments and First Quarter 2026 Highlights
Since the beginning of 2026, NeuroSense has continued to strengthen PrimeC's position through significant clinical and scientific milestones. The Company reported statistically significant survival data from its Phase 2b study, demonstrating a
Further reinforcing the strength of its clinical package, results from the PARADIGM trial were published in JAMA Neurology, highlighting meaningful clinical outcomes and biological activity, including biomarker changes consistent with the proposed mechanism of action.
NeuroSense also expanded its scientific visibility through presentations at leading international conferences and strengthened its intellectual property portfolio with newly granted patents in
Upcoming Expected Milestones
- Additional biomarkers readouts from PARADIGM
- Readouts from the Phase 2 Alzheimer's study
- Planned pre-NDS meeting with Health Canada in May 2026
- Potential NDS submission in
Canada , subject to regulatory feedback - Continued preparation for initiation of the Phase 3 PARAGON trial in ALS
Financial Results
Research and development expenses for the years ended December 31, 2025 and 2024 were
General and administrative expenses for the years ended December 31, 2025 and 2024 were
As of December 31, 2025, NeuroSense had cash of approximately
A summary of NeuroSense's consolidated financial results is included in the tables below.
A copy of the Company's annual report on Form 20-F for the year ended December 31, 2025 has been filed with the
NeuroSense Therapeutics Ltd. | ||||
Consolidated Statements of Financial Position | ||||
( | ||||
As of December 31, | ||||
2025 | 2024 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ | 166 | $ 3,378 | |
Other receivables | 565 | 989 | ||
Restricted deposits | 47 | 35 | ||
Total current assets | 778 | 4,402 | ||
Non-current assets: | ||||
Property and equipment, net | 58 | 66 | ||
Right of use assets | 170 | 84 | ||
Restricted deposit | 22 | 23 | ||
Total non-current assets | 250 | 173 | ||
Total assets | $ | 1,028 | $ 4,575 | |
Liabilities and shareholders' equity | ||||
Current liabilities: | ||||
Trade payables | $ | 799 | $ 1,160 | |
Other current liabilities | 1,717 | 832 | ||
Total current liabilities | 2,516 | 1,992 | ||
Non-current liabilities: | ||||
Lease liability less current maturity | 72 | - | ||
72 | - | |||
Total liabilities | 2,588 | 1,992 | ||
Shareholders' equity (deficit): | ||||
Ordinary shares, no par value: | ||||
Authorized: 90,000,000 shares at December 31, 2025 and December 31, 2024; | - | - | ||
Share Premium and Capital Reserve | 46,225 | 39,243 | ||
Accumulated deficit | (47,785) | (36,660) | ||
Total shareholders' equity (deficit) | (1,560) | 2,583 | ||
Total liabilities and shareholders' equity | $ | 1,028 | $ 4,575 | |
NeuroSense Therapeutics Ltd. | ||||||
Consolidated Statements of Income and Comprehensive Loss | ||||||
( | ||||||
For the years ended | ||||||
2025 | 2024 | 2023 | ||||
Research and development expenses | $ | (6,227) | $ (5,698) | $ (7,274) | ||
General and administrative expenses | (4,858) | (4,204) | (4,775) | |||
Operating loss | (11,085) | (9,902) | (12,049) | |||
Financing income (expenses), net | (40) | (308) | 1,942 | |||
Net loss and comprehensive loss | $ | (11,125) | $ (10,210) | $ (10,107) | ||
Basic and diluted net loss per share | $ | (0.44) | $ (0.54) | $ (0.74) | ||
Weighted average number of ordinary shares used in computing | 25,481,343 | 18,602,082 | 13,640,168 | |||
NeuroSense Therapeutics Ltd. | |||||||||||
Consolidated Statements of Changes in Equity (deficit) | |||||||||||
( | |||||||||||
Ordinary | Share | Accumulated | Total | ||||||||
Number | Amount | Reserve | Deficit | (Deficit) | |||||||
Balance as of January 1, 2023 | 11,781,963 | $ - | $ 21,858 | $ (16,014) | $ 5,844 | ||||||
Issuance of shares and pre-funded warrants, net | 1,333,600 | - | 806 | - | 806 | ||||||
Exercise of pre-funded warrants, options and vested RSUs | 2,263,479 | - | - | - | - | ||||||
Share based compensation | - | - | 1,698 | - | 1,698 | ||||||
Net loss and comprehensive loss | - | - | - | (10,107) | (10,107) | ||||||
Balance as of December 31, 2023 | 15,379,042 | $ - | $ 24,362 | $ (26,121) | $ (1,759) | ||||||
Issuance of shares and pre-funded warrants, net | 5,981,238 | - | 10,806 | - | 10,806 | ||||||
Exercise of pre-funded warrants, options and vested RSUs | 1,573,000 | - | (*) | - | (*) | ||||||
Issuance of shares due to SEPA agreement | 224,697 | 281 | - | 281 | |||||||
Reclassification of warrants into equity | - | - | 1,695 | (329) | 1,366 | ||||||
Bonus accrual reclassification to equity | - | - | 1,434 | - | 1,434 | ||||||
Share-based compensation | 70,964 | - | 665 | - | 665 | ||||||
Net loss and comprehensive loss | - | - | - | (10,210) | (10,210 | ||||||
Balance as of December 31, 2024 | 23,228,941 | $ - | $ 39,243 | $ (36,660) | $ | $ 2,583 | |||||
Issuance of shares, net | 3,546,528 | - | 4,410 | - | 4,410 | ||||||
Exercise of options, pre funded warrants and vested RSUs | 1,583,000 | - | 22 | - | 22 | ||||||
Conversion of liability into shares | 476,435 | - | 410 | - | 410 | ||||||
Share based compensation | 3,722,270 | - | 2,140 | - | 2,140 | ||||||
Net loss and comprehensive loss | - | - | - | (11,125) | (11,125 | ||||||
Balance as of December 31, 2025 | 32,557,174 | - | 46,225 | (47,785) | (1,560 | ||||||
(*) less than | |||||||||||
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
About PrimeC
PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.
About ALS
Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, reporting of data, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-reports-year-end-2025-financial-results-and-provides-business-update-302730062.html
SOURCE NeuroSense